]>
IRCT20220422054617N1 IRCT 2022-07-10 Shiraz University of Medical Sciences the effect of rivaroxaban on the prevention of deep vein thrombosis in nephrotic syndrom evaluation of the effect of rivaroxaban in comparison with warfarin in preventing deep vein thrombosis in patients with nephrotic syndrom 2022-07-23 anticipated 20 Complete https://irct.ir/trial/63187 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: The sampling method in this study is a random permutation block of four. The sampling method is that A represents the Case group (preventive with rivaroxaban drug) and B represents the control group (preventive with warfarin drug). The number of different situations is six as follows. It is ABBA, BAAB, BBAA, AABB, ABAB, BABA. We assign a number to each of these states. By using the table of random numbers, a list of twenty people (five blocks of four) is produced. 3 Nephrotic syndrom. Intervention 1: Control group: prophylaxis with warfarinTen patients are treated with warfarin as a control group and at the beginning of the study and once every three months until the albumin is less than 2.5, they undergo color Doppler ultrasound of deep renal veins and lower extremities. The number range is 2 to 3. Intervention 2: Intervention group: under prevention with rivaroxabanAnother 10 patients are prevented with Rivaroxaban 10 mg orally daily and at the beginning and once every three months undergo deep calorie doppler ultrasound. Both groups are prevented with drug and sonography until the albumin is less than 2.5 they take. Yes - There is a plan to make this available What will be shared: Data can potentially be shared after not identifying individuals When: One month after printing the results To whom: Academic and scientific institutions Conditions: No special conditions are required Where to obtain: Arash.nik0000@gmail.com How to obtain: Request by email Comments:
public Maryam Shafiee
Namazi hospital.zand
Shiraz Iran (Islamic Republic of) ... +98 917 331 1849 Arash.nik0000@gmail.com Shiraz University of Medical Sciences scientific Mitra Rasouli asl
No. 8, Farhangian Alley, 1st Alley, Farhangian Alley
Shiraz Iran (Islamic Republic of) 6361983131 +98 61 5272 0315 Arash.nik0000@gmail.com Shiraz University of Medical Sciences Iran (Islamic Republic of) Newly diagnosed nephrotic syndrome Albumin less than 2.5 in a patient with MGN Albumin less than 2 in other cases of nephrotic syndrome The age of the patient is between 18 and 60 years The patient's bleeding risk according to HAS-BLED criteria is low to moderate risk GFR greater than 60 18 years 60 years Both coagulation disorders pregnancy active cancer taking aspirin taking plavix N04 Nephrotic syndrome Prevention Prevention Control group: prophylaxis with warfarinTen patients are treated with warfarin as a control group and at the beginning of the study and once every three months until the albumin is less than 2.5, they undergo color Doppler ultrasound of deep renal veins and lower extremities. The number range is 2 to 3 Intervention group: under prevention with rivaroxabanAnother 10 patients are prevented with Rivaroxaban 10 mg orally daily and at the beginning and once every three months undergo deep calorie doppler ultrasound. Both groups are prevented with drug and sonography until the albumin is less than 2.5 they take Deep vein thrombosis after taking rivaroxaban. Timepoint: At the beginning of the study and once every three months. Method of measurement: Color Doppler ultrasound of the deep veins of the lower extremities and renal arteries. Shiraz University of Medical Sciences Approved 2022-04-03 Ethics committee of Shiraz University of Medical Sciences No. 8, the first alley of Farhangian alley, Telemim street behbahan Khouzestan Iran (Islamic Republic of)